Popular opinion is that two big shifts have changed the game for bioinformatics. The first is a technology development—single cell ‘omics—that began just over 10 years ago, the other is a more recent move to a new model of drug discovery that looks to leverage the vast amounts of human genetic data now being generated in support of precision medicine.
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Interview with Marilyn Matz, CEO and Co-founder at Paradigm4, and 2020 NACD Directorship 100™ honoree, and her colleague Dr. Zachary Pitluk, VP of Life Sciences and Health Care at Paradigm4. Founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker, Paradigm4 is not just any data analytics company
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
